Valuable Targets

TPO receptor agonists: What They Are and How to Stay Updated on the Latest Research

8 January 2024
3 min read

The TPO receptor, also known as the thrombopoietin receptor, plays a crucial role in the human body's production of platelets. Thrombopoietin, a hormone produced in the liver and kidneys, binds to the TPO receptor, stimulating the production and maturation of megakaryocytes, which are the precursor cells of platelets. This interaction is essential for maintaining adequate platelet levels in the blood, which are vital for normal blood clotting and preventing excessive bleeding. Understanding the TPO receptor's function has led to the development of drugs that target this receptor, offering potential therapeutic options for conditions associated with low platelet counts, such as immune thrombocytopenia and chemotherapy-induced thrombocytopenia.

The analysis of the target TPO receptor reveals a competitive landscape with multiple companies actively involved in research and development. The highest stage of development is the "Approved" phase, with several companies having drugs in this phase. Thrombocytopenia and Purpura, Thrombocytopenic, Idiopathic are the most common indications for drugs under this target. Small molecule drugs, Fusion proteins, and Biosimilars are progressing most rapidly, indicating intense competition. China, the United States, the European Union, and Japan are the leading countries in terms of development under this target. Further analysis is required to understand the specific R&D progress of each company, the research institutions involved in biosimilar development, and the factors contributing to the progress in China.

How do they work?

TPO receptor agonists are a type of medication that act on the thrombopoietin (TPO) receptor in the body. Thrombopoietin is a hormone that regulates the production of platelets, which are essential for blood clotting. TPO receptor agonists mimic the action of thrombopoietin and stimulate the production of platelets in the bone marrow.

From a biomedical perspective, TPO receptor agonists are used in the treatment of certain medical conditions that result in low platelet counts, such as immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. By increasing platelet production, these medications help prevent bleeding episodes and improve overall blood clotting function.

TPO receptor agonists can be administered orally or through injection, depending on the specific drug. They work by binding to the TPO receptor on the surface of bone marrow cells, which triggers a signaling cascade leading to increased platelet production. These medications are typically used when other treatments, such as corticosteroids, have been ineffective or are not suitable for the patient.

It is important to note that TPO receptor agonists may have potential side effects, such as headache, nausea, fatigue, and muscle pain. Close monitoring of platelet counts and regular follow-up with a healthcare professional are necessary during treatment with these medications to ensure optimal effectiveness and safety.

List of TPO receptor Agonists

The currently marketed TPO receptor agonists include:

For more information, please click on the image below.

电脑屏幕截图

描述已自动生成

What are TPO receptor agonists used for?

TPO receptor agonists are used in the treatment of certain medical conditions that result in low platelet counts, such as immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. For more information, please click on the image below to log in and search.

日程表

描述已自动生成

How to obtain the latest development progress of TPO receptor agonists?

In the Synapse database, you can keep abreast of the latest research and development advances of TPO receptor agonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

Coherus Reveals the Introduction of LOQTORZI™ in the United States Market
Latest Hotspot
4 min read
Coherus Reveals the Introduction of LOQTORZI™ in the United States Market
8 January 2024
Coherus BioSciences, Inc. has recently declared that their product, LOQTORZI™ (toripalimab-tpzi), can now be acquired from certain specialty distribution channels within the U.S. market.
Read →
How many types of patent certifications are available to file an ANDA?
Knowledge Base
2 min read
How many types of patent certifications are available to file an ANDA?
8 January 2024
When submitting an ANDA, generic drug manufacturers need to submit one of the following four statements in accordance with the provisions of the Orange Book.
Read →
FDA Approves Atom Bioscience to Conduct Human Trials with ABP-745 for Sudden Gout Flare-ups
Latest Hotspot
3 min read
FDA Approves Atom Bioscience to Conduct Human Trials with ABP-745 for Sudden Gout Flare-ups
8 January 2024
Atom Bioscience, a biotech company specializing in innovative therapies for inflammation and metabolic diseases, announced FDA approval for the Phase 1 trial of its new drug, ABP-745.
Read →
What are GLP-1R agonists and how do you quickly get the latest development progress?
What are GLP-1R agonists and how do you quickly get the latest development progress?
8 January 2024
GLP-1R agonists are medications that regulate glucose metabolism and are used in the treatment of type 2 diabetes and obesity.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.